View Older Stories

Mar 31, 2026 06:46AM Jasper Therapeutics (JSPR) Misses Q4 EPS by 32c

Mar 23, 2026 06:19AM UBS Assumes Jasper Therapeutics (JSPR) at Neutral

Jan 13, 2026 07:19AM Rodman & Renshaw Starts Jasper Therapeutics (JSPR) at Buy

Jan 9, 2026 04:33AM Jasper Therapeutics (JSPR) Reiterated at Market Outperform by Citizens

Jan 8, 2026 07:03AM Jasper Therapeutics reports positive briquilimab data for urticaria treatment

Dec 3, 2025 04:57AM Jasper Therapeutics (JSPR) Internal Investigation Exonerates Product - Citizens

Dec 2, 2025 07:01AM Jasper Therapeutics reports positive data from asthma study

Nov 11, 2025 08:41AM Jasper Therapeutics (JSPR) PT Lowered at RBC Capital as 'BEACON Investigation Raises Further Questions'

Nov 10, 2025 05:08PM Jasper Therapeutics (JSPR) Misses Q3 EPS by 113c

Sep 25, 2025 10:46AM Grabar Law Office Investigates Claims on Behalf of Shareholders of Jasper Therapeutics, Inc. (JSPR)

Sep 22, 2025 04:25AM Jasper Therapeutics (JSPR) PT Lowered to $6 at Citizens JMP

Sep 19, 2025 01:47PM Jasper Therapeutics (JSPR) PT Lowered to $7 at BTIG

Aug 14, 2025 05:32AM BTIG Reiterates Buy Rating on Jasper Therapeutics (JSPR)

Aug 14, 2025 04:18AM Citizens JMP Reiterates Market Outperform Rating on Jasper Therapeutics (JSPR)

Jul 10, 2025 04:23AM Citizens JMP Reiterates Market Outperform Rating on Jasper Therapeutics (JSPR)

Jul 9, 2025 08:01AM Jasper Therapeutics cuts workforce by 50% to extend cash runway

Jul 8, 2025 10:13AM Jasper Therapeutics (JSPR) PT Lowered to $29 at UBS

Jul 8, 2025 04:02AM Jasper Therapeutics (JSPR) PT Lowered to $12 at Citizens JMP

Jul 7, 2025 04:47PM BMO Capital Downgrades Jasper Therapeutics (JSPR) to Market Perform

Jul 7, 2025 04:12PM Jasper Therapeutics (JSPR) PT Lowered to $20 at Evercore ISI

Jul 7, 2025 03:29PM Cantor Fitzgerald Downgrades Jasper Therapeutics (JSPR) to Neutral, 'Scratching our Heads with Today’s Briq’ Update'

Jul 7, 2025 02:23PM TD Cowen Reiterates Buy Rating on Jasper Therapeutics (JSPR)

Jul 7, 2025 01:54PM Jasper Therapeutics (JSPR) PT Lowered to $20 at BTIG

Jul 7, 2025 01:16PM William Blair Downgrades Jasper Therapeutics (JSPR) to Market Perform

Jul 7, 2025 11:14AM Jasper Therapeutics (JSPR) PT Lowered to $20 at H.C. Wainwright

Jul 7, 2025 07:31AM Jasper Therapeutics (JSPR) reports mixed results from urticaria drug trial

Jun 17, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)

Jun 16, 2025 04:18AM Citizens JMP Reiterates Market Outperform Rating on Jasper Therapeutics (JSPR)

Mar 19, 2025 04:18PM Jasper Therapeutics (JSPR) Files $200M Mixed Shelf

Mar 12, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)

Mar 3, 2025 02:51PM Oppenheimer Reiterates Outperform Rating on Jasper Therapeutics (JSPR)

Mar 3, 2025 09:23AM Stifel Reiterates Buy Rating on Jasper Therapeutics (JSPR)

Mar 3, 2025 08:48AM Cantor Fitzgerald Reiterates Overweight Rating on Jasper Therapeutics (JSPR)

Feb 28, 2025 08:02AM Jasper Therapeutics (JSPR) Announces Late-Breaking Briquilimab Presentation

Feb 18, 2025 04:21AM JMP Securities Reiterates Market Outperform Rating on Jasper Therapeutics (JSPR)

Jan 9, 2025 11:40AM Jasper Therapeutics (JSPR) PT Lowered to $48 at RBC Capital; Stock Pressured Following BEACON's Initial Data

Jan 8, 2025 03:13PM Jasper Therapeutics (JSPR) PT Lowered to $64 at BTIG

Jan 8, 2025 12:33PM Oppenheimer on Jasper (JSPR): 'adding cohorts and remains on track to begin a registrational program in CSU with a Ph2b study expected to initiate in 2H25'

Jan 8, 2025 12:18PM Guggenheim on Celldex Therapeutics (CLDX): 'CLDX Remains Leader In The Mast Cell Space'

Jan 8, 2025 12:03PM Stifel on Celldex (CLDX) and Third Harmonic Bio (THRD): 'we continue to like the prospects of CLDX and THRD as both first-in-class and an oral pure-play'

Jan 8, 2025 12:00PM Citi on Celldex Therapeutics (CLDX): 'Competitor CSU Data Unclear Under the Surface; Positive Readthrough for Celldex'

Jan 8, 2025 11:56AM H.C. Wainwright on Jasper Therapeutics (JSPR): 'We believe briquilimab data bode well competitively'

Jan 8, 2025 11:16AM BMO Capital Reiterates Outperform Rating on Jasper Therapeutics (JSPR)

Jan 8, 2025 07:37AM Jasper Therapeutics (JSPR) Falls 40% Following Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 8, 2025 07:01AM Jasper Therapeutics (JSPR) Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 2, 2025 04:00PM Biotech outlook for 2025: Stifel

Jan 2, 2025 10:56AM Stifel Highlights Iovanace Biotherapeutics (IOVA) as 'Top Pick' in Biotech's 2025 Outlook Note

Jan 2, 2025 06:35AM Oppenheimer Reiterates Outperform Rating on Jasper Therapeutics (JSPR)

Dec 5, 2024 04:06PM BMO Capital Starts Jasper Therapeutics (JSPR) at Outperform

Oct 15, 2024 06:35AM H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)

View Older Stories